Skip to main content
Sign In

Clinical Trials

Volunteer to Be Part of a Research Study


You can search for specific diseases or conditions in our Clinical Trials list (the page takes a few seconds to load due to the quantity of trials).

Page through all School of Medicine clinical and research trials below, or click here to look for specific types of trials.
(It will take a few seconds to load) There are two categories: 

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please submit your Web ad here.  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
Page Size
 |  Displaying page 1 of 4, items 1 to 30 of 102.
COMIRB Approved Advertisement TitleStudy GoalsEligibility CriteriaDate Posted
Data pager
Page Size
 |  Displaying page 1 of 4, items 1 to 30 of 102.
If you child suffers from rashes or skin allergies he or she may qualify to take part in a research study.
To test seven new antigens on the child and adolescent population to add to the current standard test
Children and adolescents 6-17 diagnosed with contact dermatitis or may have contact dermatitis who are willing to wear test patches for 2 days and are available for follow-up visits
Investigations in Gestational Origins of Lifetime Development: Understanding health begins before birth. Are you in your first trimester of Pregnancy?
To learn more about how your metabolism is connected to your baby's growth and development
Healthy Women ages 18-35 who are 10-14 weeks pregnant with single baby.  Norm BMI or 30-38 who are willing to complete 5 visits during pregnancy and agreeable to an infant blood draw at birth and DXA postpartum.  Delivery must be at University of Colorado Hospital.  there is an option to take part in a 1 year follow-up which entails an additional 4 visits and another DXA at 1 year of life.
We are Currently Enrolling People with Down syndrome for a study in Dr. Pelak's Brain and Vision Research lab at the University of Colorado Anschutz Medical Campus.
To examine visual brain function in people with mild memory impairments to detect early signs of Alzheimer's Disease.​
Persons 19-30 who have Down Syndrome
You are invited to participate in EMERALD, as research study about Metformin and Type 1 Diabetes in Adolescents
​To determine the effects of Metformin on Cardiovascular Function in Adolescents with Type 1 Diabetes.
Persons 12-21 who have Type 1 Diabetes, non-smoker and exercise no more than 3 hours a week.  You must be willing to take metformin or placebo (sugar pill) for 3 months.   Other exclusions apply, please contract study for more information
Children's Hospital, department of Pediatric Neurology is conducting a research study
Evaluating the effects of a single treatment of injected BOTOX® (Botulinum Toxin Type A) for chronic migraine(s) in adolescents.
Adolescents 12-17 who have no serious medical conditions but have at least 15 headaches a month for the last 6 months. You not have any previous BOTX treatments or are not currently using any prophylactic medicine.
Non-Alcoholic Fatty Liver Disease and Obstructive Sleep Apnea: Mechanistic Links between Hypoxemia and Liver Injury
To learn if obstructive sleep apnea and low oxygen levels have a role in developing Non-Alcoholic Fatty Liver Disease (NAFLD).​​​
Children 10-17 who have a normal weight and no serious medical problems
Are you using Implanon or Nexplanon for birth control?
Study on a potential treatment for bothersome bleeding/spotting related to the etonogestrel implant.
Women 18-44 who are experiencing bothersome bleeding/spotting while using Implanon or Nexplanon
Exercise and Cancer Prevention Research Study
The goal of this study is to better understand the biological mechanisms associated with exercise and reduced risk for breast cancer.
You must be a female between the ages of 30-45 to participate in this study. You must be planning to live in the Denver metropolitan area for the next 10 consecutive months. You should not be a regular exerciser because this study is for people who do not exercise right now; however, you should be willing to participate in an exercise program 4 times per week for 16-weeks.
Are you interested in a supervised exercise intervention?
Volunteers are needed for a research study to examine the effects of exercise on food intake and appetite regulation.
- 21-45 years old - Non- smoker - Non- Diabetic - Exercise no more than 1 time a week - Maintained your current weight for last 6 months - Have a body mass index (BMI) of 27-35 (check it out at
Study of Mood Disorder in Preschool Children
We are doing a research study to better understand what mood disorders look like in preschool children.
We are looking for volunteers who:   *    Are parents of children between the ages of 4 and 6 years 0 months.  *    Are in one of three groups:         1) Their child has no major mental health problems, and there is            no family history of major mood or psychotic disorders.          2) Their child has been diagnosed with a mood disorder, bipolar disorder, or              mood dysregulation disorder.  3) Their child has been diagnosed with attention deficit hyperactivity  disorder (ADHD).  Parents or guardians will be asked to:                *    Read and sign a consent form               *    Participate in interviews about their children. The  children will be asked to:    *    Participate in a story game    *    Take tests of verbal and nonverbal abilities   How much time will this take? The visit for the child will last from 1 to 2 hours.  The visit for the parents will last 3 to 5 hours.
MRI and Questionnaire Research Study for Patients with MS Taking Tysabri and Healthy Controls
This research study plans to learn more about the differences in brain scans and self-reported quality of life between MS patients taking natalizumab (Tysabri) and individuals without MS.
-A relapsing Multiple Sclerosis patient 18-55 years old who has been taking Tysabri (natalizumab) for at least 2 years OR -A healthy individual 18-55 years old without Multiple Sclerosis or other neurological conditions
Understanding how Tysabri and Gilenya Influence the Quality of your Daily Life with Multiple Sclerosis
The purpose of this research study is to compare two medications, Tysabri and Gilenya, used in the treatment of multiple sclerosis (MS), through a few self reported patient surveys. We will ask you to complete online surveys about overall health-related quality of life, disability, fatigue, cognition and productivity. We will also want to review your medical records to understand your MS history with your permission. This study will help us understand how these drugs are impacting each aspect of your daily lives.
-Between ages 16 and 65 -Scheduled to start natalizumab or fingolimod for the first time to treat your MS
Brown Adipose Tissue and Estrogen (BATE Study)
To investigate whether estrogen influences the activity of brown adipose tissue.
Healthy non-smoking women 20-40 who have regular menstrual cycles and are not on hormonal contraceptives and exercise more than once per week
Type 2 Diabetes and Exercise Research Study
Perceived exertion during exercise
Person 50-70 with or without Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure.  You should have a BMI between 25-35 and have not smoked for a least one year.
Is your child 6-18 years old and interested in participating in a research study?
To study the effects of polycystic kidney disease (PKD) on blood vessel function
Children 6-22 free from kidney disease and other chronic diseases
Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Lipohypertrophy Study
This study is looking at evaluating Insulin Pump Infusion sites and Continuous Glucose Monitoring sites in tissue with Lipohypertrophy. We will also be looking at using the sites for a longer duration.
Lipohypertrophy site of 3 cm or greater in diameter Ages 12-45 inclusive A1C Value of < 10% Insulin pump use of at least 3 month duration Pump use with Medtronic, Animas or T-slim Willing to wear two CGM's during the 4 weeks of the study
Are you trying to lose weight?
Volunteers needed for a research study about the weight loss medication Phentermine  
Healthy and between 30-45 years of age •Have a BMI between 30 and 40 (calculate your BMI at •Willing to take the weight loss medication Phentermine for a period of 8 weeks (but not currently taking any approved or investigational medication for weight loss)
Participants Ages 12-15 years old Needed for Research Study
To learn about how children with absence epilepsy compare to healthy children in areas such as behavior, neuropsychological skills and quality of life.
Healthy hispanic individuals who are 12-15 years; No history of seizures, seizure like episodes, neurological diseases or a loss of consciousness greater than 5 minutes in their immediate family
Are you stopping your birth control because you want to become pregnant?
To look at contraception rates after birth control discontinuation.
Women 18-35 who are planning to, or have recently stopped their birth control because they want to become pregnant.
Healthy Postmenopausal Women needed to participate in a research study
To test whether estrogen has different effects on blood sugar early in menopause compared to many years after menopause​.​
Women 45-70 who have gone through menopause within the past 6 years or are more than 10 years past menopause, never used hormone therapy for more than 6 months and are willing to use estrogen patches for 1 week.  Must be a non-smoker and sedentary to moderately active.
Type 1 Diabetes Research Study
To study the effects of a medication on metabolism and blood vessel function.
Persons 25-50 years old with or without type 1 diabetes with normal blood pressure and exercise vigorously no greater than 3 times per week.
This study will look at the body's immune response (how the body fights infection) to the onset of shingles. 1-2 study visits for blood draws, over the course of 3 months.
18+ years of age; NO PRIOR HISTORY of shingles; have NEVER received the shingles vaccine; have DEVELOPED SHINGLES within the last 10 days.
Shingles Vaccine Clinical Research Trial
This study will compare responses to two shingles vaccines - the current FDA approved shingles vaccine and an investigational shingles vaccine in younger and older people.
50-59 years of age or 70-85 years of age; General good health; No prior history of shingles; Have never received the shingles vaccine; although... a subset of 70-85 year olds who DID receive the shingles vaccine at least 5 years previously is also needed (must be able to provide documentation of vaccination)
protein and infant growth: Do you have a child younger than 6 months
Participants in this research study on protein from complementary foods (meat or dairy) and infant growth, will learn how protein consumption affects your child’s growth, fat gain, and gut health from 6 to 12 months of age.  
To qualify, you child needs to be: 1. Formula fed, or not on breast-milk longer than 1 month. 2. Younger than 6 months. 3. Generally healthy. You will receive commercially available complementary foods for 7 months, Receive infant formula at no cost for 7 months, You will know your child's body fat and fat free mass and blood lipid level.
Volunteers Needed: Thinking and Memory in Parkinson's Disease
This research study aims to better understand how changes in brain activity may be related to thinking problems in Parkinson's Disease and to determine whether, by stimulating certain areas, thinking and memory can be improved.
Person's with Parkinson's Disease with mild thinking and memory problems. Between 40-90 years old. No metal in your body. No implant. Not taking any medication to improve memory. Not taking stimulants or seizure medication.
Diabetic Male and Female Volunteers Needed for Exercise Research Study
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin.  Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
Trouble Controlling your Type 2 Diabetes?
Investigational non-surgical device that may help decrease blood sugar.
Adults 21-65 with type 2 Diabetes and not on oral medication, not taking insulin. Must have an A1C level of 8-10%, be overweight or obese and willing to attend study visits
To learn more about the medical marijuana industry in Colorado and its relationship to health risk behaviors and healthcare.
Persons 18+ currently a medical marijuana patient or currently using non-medical marijuana
Volunteers needed for a research study of men who are carriers of the Fragile X gene
Study the effects of the Fragile X Tremor-Ataxia Syndrome (FXTAS) on mental abilities and brain functioning.  A better understanding of FXTAS should lead to improved diagnosis, and eventually to means of treating both the symptoms and the disease.
Men age 62 or above who have a least 12 years of education and who have no neurological disorders.
Persons with active, moderate to severe ulcerative colitis needed
This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.
Inclusion: Ages 18-70 Ulcerative colitis has been diagnoses by routine criteria At least one of the following applies: steroid dependent failed 5-ASA (mesalamine) therapy, such as Asacol Failed/lost response to infliximab (Remicade) Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (purinethol) therapy Exclusion (partial): Existing pregnancy, lactation, or planned pregnancy (men and women)

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
Page Size
 |  Displaying page 1 of 16, items 1 to 30 of 451.
Protocol TitlePI NameInstitution Number
Data pager
Page Size
 |  Displaying page 1 of 16, items 1 to 30 of 451.
Eisenmenger Quality Enhancement Research Initiative (QuERI). Sponsor Protocol 20111728. WIRB Protocol No. 20111728
Kay, Joseph12-0926
A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System. Sponsor Protocol # 09-07. WIRB Protocol # 20131128
Pollyea, Daniel13-2064
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients. Sponsor Protocol No. CMX001-301. WIRB Protocol No. 20131501
Gutman, Jonathan13-2441
A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML). Sponsor Protocol No. M14-212. WIRB Protocol No. 20131839
Pollyea, Daniel13-2463
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer. Sponsor Protocol No. I4J-MC-HHBB(e). WIRB Protocol No. 20101374
Lewis, Karl13-2557
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab Patients with Advanced Melanoma. Sponsor Protocol No. 006. WIRB Protocol No. 20130483
Gonzalez, Rene13-2581
Phase I Study of Platinum-based Chemoradiotherapy (CRT) with Oral Rigosertib in Patients with Intermediate or High-risk Head and Neck Squamous Cell Carcinoma. Sponsor Protocol No. 09-12. WIRB Protocol No. 20132209
Jimeno, Antonio13-2591
A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment. Sponsor Protocol No. 1042-0603. WIRB Protocol No. 20131531
Strom, Laura13-2603
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies. Sponsor Protocol No. 52M51-001. WIRB Protocol No. 20121889
Gore, Lia13-2642
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886)(Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV) (SELECT-1). Sponsor Protocol No. D1532C00079. WIRB Protocol No. 20131837
Oton, Ana13-2647
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
Lam, Elaine13-2806
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal. Sponsor Protocol No. MDV3100-12. WIRB Protocol No. 20131280
Elias, Anthony13-2892
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Sponsor Protocol No. VRXP-A202. WIRB Protocol No. 20131627
Jimeno, Antonio13-2911
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. Sponsor Protocol No. E5501-G000-311. WIRB Protocol No. 20131907
Everson, Greg13-2914
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
A Multicenter, Randomized, Open-Label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Advanced Multiple Myeloma. Sponsor Protocol No. ARRAY-520-216. WIRB Protocol No. 20131633
Smith, Clayton13-2932
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. MDV3100-14. WIRB Protocol No. 20131112
Crawford, E13-2937
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant. Sponsor Protocol No. C31001. WIRB Protocol No. 20132212
Diamond, Jennifer13-2999
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2+ metastatic breast cancer. Sponsor Protocol No. ONT-380-005. WIRB Protocol No. 20140127
Borges, Virginia13-3000
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. XL184-210. WIRB Protocol No. 20140076
Flaig, Thomas13-3004
A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women. Sponsor Protocol No. V98_12. WIRB Protocol No. 20140324
Gibbs, Ronald13-3019
GORE® HELEX® Septal Occluder/GORE® Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients with Patent Foramen Ovale (PFO). Sponsor Protocol No. HLX 06-03. WIRB Protocol No. 20080907
Kim, Michael13-3034
A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure. Sponsor Protocol No. HW004-A. WIRB Protocol No. 20131526
Cleveland, Joseph13-3039
A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults. Sponsor Protocol No. GS-US-292-0119. WIRB Protocol No. 20131690
Campbell, Thomas13-3072